AUTO-1/22 is under clinical development by Autolus Therapeutics and currently in Phase II for Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia). According to GlobalData, Phase II drugs for Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) have a 36% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how AUTO-1/22’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
AUTO-1/22 overview
AUTO-1NG is under development for the treatment of relapsed or refractory acute lymphoblastic leukemia, Burkitt lymphoma in pediatrics. It is a chimeric antigen receptor (CAR) T cell therapy comprising of CD19 CAR of AUTO-1 and a novel CD22 CAR. The drug candidate acts by targeting CD19 and CD22 expressing cancer cells.
It was under development for the treatment of acute myelocytic leukemia (AML, acute myeloblastic leukemia), chronic lymphocytic leukemia (CLL), chronic myelocytic leukemia (CML, chronic myeloid leukemia), hairy cell leukemia, Hodgkin lymphoma (B-cell Hodgkin lymphoma).
Autolus Therapeutics overview
Autolus Therapeutics (Autolus) is a biopharmaceutical company that specializes in the development of advanced autologous T cell therapies. It focuses on creating treatments for patients with cancer and autoimmune diseases. The company’s lead therapeutic candidate is obe-cel, a chimeric antigen receptor (CAR) T cell therapy designed to recognise and eradicate cancer cells. Autolus’ products are primarily used in the healthcare industry, specifically in the treatment of hematological malignancies and solid tumors. The company’s target market includes patients suffering from cancer and autoimmune diseases, with a particular focus on adult acute lymphoblastic leukemia (ALL), B-cell Non-hodgkin lymphoma (B-NHL), and pediatric ALL. Autolus Therapeutics is headquartered in London, England, the UK.
For a complete picture of AUTO-1/22’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
